医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences

2019年06月03日 PM09:00
このエントリーをはてなブックマークに追加


 

CHENGDU, China

HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Gilead.

“We are delighted to enter this collaboration with Gilead, an industry leader in pharmaceutical research and development. We believe the collaboration reinforces the role and reputation of HitGen’s platform in the rapidly developing field of DNA-encoded chemistry. We will work closely with Gilead scientists to generate new small-molecule lead compounds for their research programs to help bring transformative medicines to patients,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.

About HitGen Inc.

HitGen is a rapidly growing biotech company with headquarters and custom-built research facilities based in Chengdu, China, with a subsidiary in the USA. HitGen has established an industry-leading platform for early-stage drug discovery research centred on DNA encoded chemical libraries (DELs). HitGen’s DELs include encoded syntheses for more than 400 billion novel, diverse, drug-like small molecule and macrocycle compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop the novel therapeutics of the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005445/en/

CONTACT

For further information, please contact:
Dr. Jin Li, Chairman &
CEO, HitGen Inc. Tel: +86 28 85197385
Dr. Barry Morgan, Chief
Scientific Officer, HitGen Inc. Tel: +1 508 840 9646

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作